Ten-Year Review of Outcomes after Surgery, Radiation, or Active Surveillance for Localized Prostate Cancer
Article Sidebar
Main Article Content
Abstract
Objective: Prostate cancer is the second most common male cancer worldwide and the fifth leading cause of death in Thailand. This research aimed to evaluate the overall survival and disease-free survival of patients with localized prostate cancer who received different treatment options for the adjustment of future treatment policies.
Method: This retrospective cohort study was conducted using secondary data analysis and phone checkup. The population included patients diagnosed with localized prostate cancer (T1 and T2) and treated by laparoscopic radical prostatectomy, radiation therapy, or active surveillance at Vajira Hospital from December 2009 to December 2019. Survival and disease-free survival were analyzed.
Results: The median overall survival was 8.60 years (95% CI, 7.95–9.24) in the laparoscopic radical prostatectomy group and 7.98 years (95% CI, 6.13–9.82) in the radiation group. No statistically significant difference was found between these two treatments (p = 0.53). The median disease-free survival was 8.45 years (95% CI, 7.73–9.18) in the laparoscopic radical prostatectomy group and 5.89 years (95% CI, 5.60–6.18) in the radiation group. Statistically significant difference was found between these two treatments (p < 0.001).
Conclusion: The disease-free survival in the laparoscopic radical prostatectomy group was significantly higher than that in the radiation group (p < 0.001). The overall survival was the same for both groups.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384(9959):2027-35.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366(11):981-90.
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360(13):1310-9.
Shoag JE, Mittal S, Hu JC. Reevaluating PSA testing rates in the PLCO trial. N Engl J Med 2016;374(18):1795-6.
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104(2):125-32.
Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Häggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11):781-9.
Bill-Axelson A, Holmberg L, Garmo H,R.Rider J, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014:370:932-42.
Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367(3):203-13.
Guillonneau B, el-Fettouh H, Baumert H, Cathelineau X, Doublet JD, Fromont G, et al. Laparoscopic radical prostatectomy: oncological evaluation after 1,000 cases a Montsouris Institute. J Urol 2003;169(4):1261-6.
Stolzenburg JU, Rabenalt R, DO M, Ho K, Dorschner W, Waldkirch E, et al. Endoscopic extraperitoneal radical prostatectomy: oncological and functional results after 700 procedures. J Urol 2005;174(4 Pt 1):1271-5; discussion 1275.
Pavlovich CP, Trock BJ, Sulman A, Wagner AA, Mettee LZ, Su LM. 3-year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: experience from a tertiary referral center in the United States. J Urol 2008;179(3):917-21; discussion 921-2.
DonovN JL, Hamdy FC, Lane JA, Jenny L, Freddie C, Athene Lane, et al. Patient-reported outcome after mornitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016;375:1425-37.
National Comprehensive Cancer Network [internet]. [cited 2022 February 5] Available from: https://www.nccn.org